Emotional Backdrop Smolders As FDA Reviews Smoking Cessation Category
Executive Summary
FDA asks for comments including evidence needed to show safety and efficacy for novel nicotine replacement therapies, but speakers at recent hearing highlight the public's psychological toll from tobacco-related deaths and the emotional connection smokers have with tobacco and nicotine.
You may also be interested in...
Health Market News: DXM Sales Age-Restriction Bill Filed, E-Cigarettes Top NRTs In UK Trial
Resp. Matsui, Johnson again introduce bill for national age-18 requirement for OTC DXM sales; E-Cigarettes top NRTs for smoking cessation efficacy in UK trial.
FDA Helps E-Cigarettes Navigate NDA Process With Nonclinical Tests Guidance
Commissioner Gottlieb highlights the first of two draft guidances US FDA will publish on developing "novel, inhaled nicotine replacement therapies that could be submitted to the FDA for approval as new drugs, similar to current" OTC nicotine replacement therapies. FDA has had a contentious history with manufacturers of electronic nicotine devices, but officials have said the products are eligible for review as NRTs through the NDA process.
FDA Helps E-Cigarettes Navigate NDA Process With Nonclinical Tests Guidance
Commissioner Gottlieb highlights the first of two draft guidances US FDA will publish on developing "novel, inhaled nicotine replacement therapies that could be submitted to the FDA for approval as new drugs, similar to current" OTC nicotine replacement therapies. FDA has had a contentious history with manufacturers of electronic nicotine devices, but officials have said the products are eligible for review as NRTs through the NDA process.